Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

Annals of Hematology
Andrea CameraFelicetto Ferrara

Abstract

A large proportion of adult patients with acute myeloid leukemia (AML) relapse after treatment, and some of them are resistant to primary induction chemotherapy. Sixty-one patients from seven hematological centers with poor-risk AML, primary refractory (n = 16), or relapsed (n = 45) were treated with a salvage regimen, including fludarabine (2 days) and cytarabine (3 days) in a sequential continuous infusion, associated with liposomal daunorubicin (3 days) (FLAD). Complete response rate was 44% and 56% for refractory and relapsed patients, respectively, with an overall response rate of 52% (32 of 61). Twenty-two patients (36%) were resistant to the salvage therapy. Seven patients (12%) died early during chemotherapy, four of them because of sepsis. Nineteen patients in complete remission (CR) underwent a stem-cell transplant (SCT) procedure: five autologous, nine from a HL-A identical sibling, and five from HL-A matched unrelated donors. Post-treatment aplasia and mucositis were major toxicities. Twenty patients (62.5%) relapsed after this treatment in a median of 7.3 months; ten patients relapsed after a SCT procedure. Nine patients are alive and disease free; three of them were rescued after a further cytotoxic treatment. The...Continue Reading

References

Sep 12, 1987·Lancet·R A SellsI T Gilmore
Dec 1, 1987·Cancer Treatment Reviews·R A SellsR E Stringer
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GillA M Levine
Jan 1, 1994·Investigational New Drugs·P GuaglianoneF Muggia
Jan 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V GandhiW Plunkett
Jul 1, 1996·Leukemia & Lymphoma·M ClavioM Gobbi
Jun 13, 1998·American Journal of Hematology·M MontilloF Ferrara
Aug 12, 1999·British Journal of Haematology·M MichieliM Baccarani
Nov 11, 1999·Investigational New Drugs·J CortesH Kantarjian
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Jul 16, 2005·Leukemia & Lymphoma·Athanasios Fassas, Achilles Anagnostopoulos

❮ Previous
Next ❯

Citations

Mar 15, 2011·Immunotherapy·Francois Fay, Christopher J Scott
Jan 25, 2013·Therapeutic Delivery·Seth M Miller, Andrew Z Wang
Oct 26, 2013·Paediatric Drugs·Jennifer DavilaThomas Renaud
Jan 6, 2010·Journal of Oncology·Biljana Culjkovic, Katherine L Borden
Sep 25, 2015·Expert Review of Anticancer Therapy·Edouard AlphandéryMickael Durand-Dubief
Jan 30, 2010·Clinical Therapeutics·Tadeusz Robak, Agnieszka Wierzbowska
Jan 24, 2019·Expert Review of Clinical Pharmacology·Juan Eduardo Megías-VericatPau Montesinos
Jan 7, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Weiwei GaoLiangfang Zhang
Mar 8, 2012·Journal of Pediatric Hematology/oncology·Paola QuarelloFranca Fagioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.